Rachel Goodwin - Concepedia

Author

Rachel Goodwin

Also Known As

R A Goodwin, R GOODWIN, R Goodwin, R. A. Goodwin, R. Goodwin, R.A. Goodwin, RACHEL A GOODWIN, RACHEL GOODWIN, Rachel A Goodwin, Rachel A. Goodwin

167

Publications

2.9K

Citations

H-Index

Concepts

All Affiliations

Ottawa Hospital Princess Margaret Cancer Centre University of Ottawa University of Toronto BC Cancer Agency

About

Rachel Goodwin is an author at Ottawa Hospital specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	15	21	962
2	Health Sciences	8	8	209
3	Public Health	4	4	81
4	Education	1	1	36
5	Behavioral Sciences	1	1	36

Rachel Goodwin

Publications

Citations

H-Index

Page 1

	Year	Citations
Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17 Stephanie Yasmin Brule, Derek J. Jonker, Christos S. Karapetis, European Journal of Cancer Gastrointestinal OncologyPrognostic FactorMedicineCancer ManagementImmunology	2015	333
Adenosine 2A Receptor Blockade as an Immunotherapy for Treatment-Refractory Renal Cell Cancer Lawrence Fong, Andrew Hotson, John D. Powderly, Cancer Discovery	2019	321
Zanidatamab, a novel bispecific antibody, for the treatment of locally advanced or metastatic HER2-expressing or HER2-amplified cancers: a phase 1, dose-escalation and expansion study Funda Meric‐Bernstam, Muralidhar Beeram, Erika Hamilton, The Lancet Oncology	2022	164
Results of the phase I CCTG IND.231 trial of CX-5461 in patients with advanced solid tumors enriched for DNA-repair deficiencies John Hilton, Karen A. Gelmon, Philippe L. Bédard, Nature Communications	2022	128
Overview of Systemic Therapy for Colorectal Cancer Rachel Goodwin, Timothy R. Asmis Clinics in Colon and Rectal Surgery Surgical OncologyGastrointestinal OncologyMedicineSystemic TreatmentPharmacology	2009	76
PROSPECT Eligibility and Clinical Outcomes: Results From the Pan-Canadian Rectal Cancer Consortium Dominick Bossé, Jamison Mercer, Soundouss Raissouni, Clinical Colorectal Cancer Surgical OncologyPatient SelectionMedicineCancer ManagementOutcomes Research	2016	71
Predictors of Pathologic Complete Response After Neoadjuvant Treatment for Rectal Cancer: A Multicenter Study Dawn Elizabeth Armstrong, Soundouss Raissouni, Julie Price Hiller, Clinical Colorectal Cancer Surgical OncologyPathologic Complete ResponseGastrointestinal OncologyMedicineCancer Recurrence	2015	67
Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation Shaan Dudani, Horia Marginean, Patricia A. Tang, BMC Cancer	2019	60
Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics James T. Topham, Joanna M. Karasinska, Michael K.C. Lee, Clinical Cancer Research	2020	59
Canadian Cancer Trials Group IND197: a phase II study of foretinib in patients with estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2-negative recurrent or metastatic breast cancer Daniel Rayson, Sasha Lupichuk, Kylea Potvin, Breast Cancer Research and Treatment Metastatic Breast CancerProgesterone ReceptorBreast OncologyMedicineEstrogen Receptor	2016	56

Page 1